Scheduled date for Ordinary General Meeting of Shareholders: June 18, 2021
Scheduled date for starting dividend payment: June 3, 2021
Scheduled date for submitting securities report: June 21, 2021
(Amounts rounded down to the nearest million yen)
1. Consolidated Results for the Year Ended March 31, 2021 (From April 1, 2020, to March 31, 2021)
(1) Consolidated Operating Results
(Percentage changes relative to previous corresponding period)
Net sales
Operating income
Ordinary income
Profit attributable to
owners of parent
Million yen
%
Million yen
%
Million yen
%
Million yen
%
March 2021
102,904
-6.4
5,786
-22.9
6,447
-21.1
6,130
-0.3
March 2020
109,983
-3.2
7,503
-16.4
8,175
-13.4
6,149
-10.5
Note : Comprehensive income: March 2021: 6,276 million yen (70.8%), March 2020: 3,674 million yen (35.7%)
Net income per share
Net income per
ROE
Ratio of ordinary
Operating income
share (Diluted)
income to total assets
margin
Yen
Yen
%
%
%
March 2021
106.99
-
5.0
3.8
5.6
March 2020
107.35
-
5.0
4.8
6.8
Note : Equity in earnings of affiliates: March 2021: 49 million yen, March 2020: 19 million yen
(2) Consolidated Financial Position
Total assets
Net assets
Equity ratio
Net assets per share
Million yen
Million yen
%
Yen
March 2021
167,126
124,661
74.6
2,175.52
March 2020
171,160
122,710
71.7
2,142.07
Note : Equity: March 2021: 124,661 million yen, March 2020: 122,710 million yen
(3) Consolidated Cash Flows
Cash flows from
Cash flows from
Cash flows from
Cash and cash equivalents
operating activities
investing activities
financing activities
at the end of year
Million yen
Million yen
Million yen
Million yen
March 2021
5,189
-4,259
-4,918
26,476
March 2020
7,739
-2,943
-5,117
30,509
2. Dividends
Dividend per share
(Record date)
End of the 1st
End of the 2nd
End of the 3rd
Year-end
Total
quarter
quarter
quarter
Yen
Yen
Yen
Yen
Yen
March 2020
-
30.00
-
45.00
75.00
March 2021
-
30.00
-
45.00
75.00
March 2022
-
20.00
-
32.00
52.00
(Forecast)
Total dividends
Payout ratio
Ratio of dividends to net
(Consolidated)
assets (Consolidated)
Million Yen
%
%
March 2020
4,361
70.9
3.5
March 2021
4,360
71.1
3.5
March 2022
112.0
(Forecast)
1
3. Forecast of Consolidated for the Year Ending March 31, 2022 (From April 1, 2021, to March 31, 2022) (Percentage changes relative to previous corresponding period)
Net sales
Operating income
Ordinary income
Profit attributable to
Net income
owners of parent
per share
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Yen
First half
47,300
-
-800
-
-600
-
-300
-
-5.24
Full year
102,600
-
3,300
-
3,800
-
2,700
-
47.12
Note : It is planned to apply "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the fiscal year ending March 2022, and the consolidated financial forecast for the fiscal year ending March 2022 incorporates these changes. Therefore, the percentage of increase / decrease from the actual results for the fiscal year ended March 31, 2021 before the application of the standards, etc. is not stated.
[Reference] It is shown below the percentage of increase / decrease under the assumption that the accounting standards are applied to the results for the fiscal year ended March 31, 2021.
Net sales
Operating income
Ordinary income
Profit attributable to
Net income
owners of parent
per share
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Yen
First half
47,300
0.3
-800
-
-600
-
-300
-
-5.24
Full year
102,600
0.8
3,300
-43.0
3,800
-41.1
2,700
-56.0
47.12
4. Other
(1) Changes in major subsidiaries during the period
(Change of specified subsidiaries associated with a change of the scope of consolidation): Yes Consolidation (Inclusion) : -
Excluded : 1 (Company name : KYORIN Medical supply Co., Ltd.)
(2) Changes in accounting policies, changes in accounting estimates and restatements
1)
Changes due to mandatory changes of accounting standards
: None
2) Changes other than 1)
: None
3)
Changes in accounting estimates
: None
4)
Restatements
: None
Number of shares issued (common stock)
Number of shares issued and outstanding at the end of the fiscal year (including treasury stock) Fiscal year ended March 2021: 64,607,936 shares,
Fiscal year ended March 2020: 64,607,936 shares
Number of shares of treasury stock at the end of the fiscal year
Fiscal year ended March 2021: 7,305,913 shares,
Fiscal year ended March 2020: 7,321,870 shares 3) Averaged number of shares of during the period
Fiscal year ended March 2021: 57,295,920 shares,
Fiscal year ended March 2020: 57,285,929 shares
This financial results report is not subject to audit procedures by Certified Public Accountants or audit firm.
Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
The Company plans to hold a financial results disclosure presentation for institutional investors and securities analysts on Wednesday, May 12, 2021. The printed materials distributed at the disclosure presentation and Supplementary
materials will be made available on the Company's website.
2
Attachments
Original document
Permalink
Disclaimer
KYORIN Holdings Inc. published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 14:55:01 UTC.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.